See the DrugPatentWatch profile for keytruda

Keytruda is a medication used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer. It is a programmed death receptor 1 (PD-1)-blocking antibody that works by enhancing the body's immune system to attack and destroy cancer cells.

Keytruda is manufactured by Merck & Co., Inc., a multinational pharmaceutical company headquartered in Kenilworth, New Jersey, United States. Merck & Co. acquired the rights to Keytruda through its acquisition of Idec Pharmaceuticals Corporation in 2003. Since then, Merck & Co. has invested heavily in the development and commercialization of Keytruda.

According to DrugPatentWatch.com, a website that tracks patent information for pharmaceutical companies, Merck & Co. holds several patents related to Keytruda, including patents for its composition, method of use, and manufacturing process. These patents provide Merck & Co. with exclusive rights to manufacture and sell Keytruda for a certain period of time.

In addition to its patents, Merck & Co. has also invested in the development of Keytruda through clinical trials and regulatory approvals. Keytruda was first approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of melanoma, and since then, it has been approved for the treatment of several other types of cancer.

In summary, Keytruda is manufactured by Merck & Co., Inc., a multinational pharmaceutical company that has invested heavily in the development and commercialization of this medication. Merck & Co. holds several patents related to Keytruda, which provide it with exclusive rights to manufacture and sell the medication.

Sources:

1. Merck & Co. Inc. (n.d.). About Us. Retrieved from <https://www.merck.com/about-us/>
2. DrugPatentWatch.com. (n.d.). Keytruda (Pembrolizumab) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/Keytruda-Pembrolizumab>
3. U.S. Food and Drug Administration. (n.d.). Pembrolizumab (Keytruda). Retrieved from <https://www.fda.gov/drugs/information-on-drugs/approved-drugs/cder-drug-product-information-pembrolizumab-keytruda>